BioCentury: Circle’s $92.5M round puts cyclin D1 program ahead of clinical lead October 5, 2026 READ MORE
Circle Pharma Strengthens Leadership Team with Promotion of Marie Evangelista, Ph.D., to Chief Scientific Officer and Addition of Mary Ellen Sillivos as SVP and Head of Human Resources September 28, 2026 READ MORE
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development September 16, 2026 READ MORE
FASEB 2026: The Cyclin D1-CDK6 Complex Drives Resistance to the CDK4-Selective Inhibitor Atirmociclib in Estrogen Receptor-Positive Breast Cancer August 4, 2026 READ MORE
Journal of Medicinal Chemistry: Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity May 7, 2026 READ MORE
AACR 2026: Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for the treatment of cancers with Rb-deficiency or hyperactivated E2F April 20, 2026 READ MORE
AACR 2026: Early clinical activity from the phase 1 evaluation of CID-078, a novel cyclin A/B RxL inhibitor, in patients with advanced solid tumors April 19, 2026 READ MORE
AACR 2026: Orally bioavailable peptide macrocycles disrupting intracellular protein-protein interactions: selective inhibitors of the RxL binding site of cyclin family proteins April 18, 2026 READ MORE
